Diagnostic and prognostic for prostate cancer

Prostate cancer is a silent killer disease in men worldwide and current diagnostic tests are inadequate.

The objective is to detect prostate cancer at an early stage to improve survival outcome for patients. QUT researchers have identified:

  • a panel of biomolecules called micro RNAs that can be detected in blood plasma to indicate the presence of prostate cancer
  • another micro RNA panel to determine which patients are likely to suffer from more aggressive disease.

Unique selling point/competitive advantage

The test would help physicians to make treatment choices and avoid the need for an invasive prostate tumour biopsy just by sampling blood plasma.

The microRNA panels also outperform the quality and reliability of the standard of care Prostate-Specific Antigen (PSA) test.

Investment or collaboration opportunities

QUT bluebox seeks an industry partner to collaborate and develop the technology.

Intellectual property rights

A provisional patent application is pending.

Contact

Patrick Dwyer
Phone: +61 7 3138 9420
Email: p.dwyer@qutbluebox.com.au

More information

Visit QUT bluebox for more information.

Also consider...